Clinical Trial Update: A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection [Phase 2]

View source ↗

Summary

Phase 2 multi-dose study of ARC-520 for chronic hepatitis B patients who are HBeAg-negative was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ARC-520

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Hepatitis B | Phase 2 | Status: TERMINATED | Results posted: 2019-04-16